Barclays increased their price target on shares of Vertex Pharmaceuticals from $384.00 to $399.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 2nd.

Source: https://www.dailypolitical.com/2023/11/23/2420-shares-in-vertex-pharmaceuticals-incorporated-nasdaqvrtx-bought-by-edgestream-partners-l-p.html

BigQuery goes further with built-in ML and Vertex AI to unlock insights across the organization.

Source: https://venturebeat.com/games/after-stadia-google-unveils-google-cloud-for-live-games/

But it’s one piece in a rapidly expanding, yet somehow cohesive environment encompassing “super-scalable AI infrastructure, Vertex AI and Duet AI assistive agents for Workspace and Google Cloud,” wrote Kurian.

Source: https://wwd.com/business-news/technology/google-cloud-gemini-pro-generative-ai-enterprise-1236074392/

California State Teachers Retirement System lowered its stake in shares of Vertex Pharmaceuticals Incorporated () by 1.8% during the 2nd quarter, according to the company in its most recent filing with the SEC.

Source: https://www.americanbankingnews.com/2023/12/14/california-state-teachers-retirement-system-sells-7960-shares-of-vertex-pharmaceuticals-incorporated-nasdaqvrtx.html

Cantor Fitzgerald reissued an “overweight” rating and issued a $380.00 target price on shares of Vertex Pharmaceuticals in a report on Thursday.

Source: https://www.americanbankingnews.com/2023/12/17/alberta-investment-management-corp-sells-183-shares-of-vertex-pharmaceuticals-incorporated-nasdaqvrtx.html

CRN breaks down the eight boldest AI remarks from Pichai on Google’s next-generation large language model (LLM) model, injecting GenAI into Threat Intelligence and other security products, Vertex AI, Duet AI and more.

Source: https://www.crn.com/news/cloud/google-ceo-s-8-boldest-ai-remarks-on-cloud-gemini-and-security

CRSP also will get $200M from its partner Vertex Pharmaceuticals () if/when exa-cel is approved.

Source: https://seekingalpha.com/article/4654099-crispr-cas9-gene-editing-is-on-the-cusp-of-something-big?source=feed_all_articles

Drive Wealth Management LLC purchased a new position in shares of Vertex Pharmaceuticals during the 1st quarter valued at $262,000.

Source: https://www.etfdailynews.com/2023/06/26/hb-wealth-management-llc-grows-stock-holdings-in-vertex-pharmaceuticals-incorporated-nasdaqvrtx/

Empirical Finance LLC lifted its position in Vertex Pharmaceuticals by 5.5% during the 2nd quarter.

Source: https://www.etfdailynews.com/2023/01/26/avantax-advisory-services-inc-has-338000-stock-holdings-in-vertex-pharmaceuticals-incorporated-nasdaqvrtx/

Evercore ISI increased their target price on shares of Vertex Pharmaceuticals from $375.00 to $379.00 in a research note on Monday, June 26th.

Source: https://www.etfdailynews.com/2023/10/21/baldwin-investment-management-llc-grows-position-in-vertex-pharmaceuticals-incorporated-nasdaqvrtx/

Finally, Macquarie Group Ltd. raised its holdings in Vertex Pharmaceuticals by 232.3% in the 2nd quarter.

Source: https://www.americanbankingnews.com/2023/09/22/level-four-advisory-services-llc-purchases-35-shares-of-vertex-pharmaceuticals-incorporated-nasdaqvrtx.html

Google is making both the Vertex AI Search and Vertex AI Conversation services generally available, providing search and chatbot capabilities to Google’s enterprise users.

Source: https://venturebeat.com/ai/google-shows-off-whats-next-for-vertex-ai-foundation-models/

Google is making both the Vertex AI Search and Vertex AI Conversation services generally available, providing search and chatbot capabilities to Google’s enterprise users.

Source: https://venturebeat.com/ai/google-shows-off-whats-next-for-vertex-ai-foundation-models/

Google’s new Vertex AI Search optimized for healthcare and life sciences is a specialized platform developed by Google Cloud to cater specifically to the needs of organizations operating within the healthcare and life sciences sector.

Source: https://www.forbes.com/sites/stevemcdowell/2023/10/11/google-clouds-vertex-ai-search-a-game-changer-for-healthcare--life-sciences/

HC Wainwright lifted their price objective on shares of Vertex Pharmaceuticals from $300.00 to $325.00 and gave the company a “buy” rating in a research note on Wednesday, February 8th.

Source: https://www.etfdailynews.com/2023/04/03/135-shares-in-vertex-pharmaceuticals-incorporated-nasdaqvrtx-purchased-by-rfp-financial-group-llc/

If you go with a managed service, the VMs run on Vertex, the company’s managed machine learning platform.

Source: https://www.networkworld.com/article/3696352/google-launches-a3supercomputer-vms.html

Independence Bank of Kentucky purchased a new position in Vertex Pharmaceuticals during the second quarter valued at approximately $25,000.

Source: https://www.dailypolitical.com/2023/08/10/canaccord-genuity-group-increases-vertex-pharmaceuticals-nasdaqvrtx-price-target-to-315-00.html

In other news, CEO sold 3,317 shares of Vertex Pharmaceuticals stock in a transaction on Thursday, April 27th.

Source: https://www.etfdailynews.com/2023/07/15/d-a-davidson-co-has-1-19-million-stock-holdings-in-vertex-pharmaceuticals-incorporated-nasdaqvrtx/

LSV Asset Management lifted its holdings in shares of Vertex Pharmaceuticals by 206.3% during the 1st quarter.

Source: https://www.dailypolitical.com/2023/05/04/barclays-boosts-vertex-pharmaceuticals-nasdaqvrtx-price-target-to-384-00.html

More recently at the European hematology conference, Vertex presented updated data from exa-cell showing pivotal trial data for beta thalassemia and sickle cell disease that met primary and key secondary endpoints.

Source: https://seekingalpha.com/article/4626362-maxcyte-inc-mxct-q2-2023-earnings-call-transcript?source=feed_all_articles